Chantrain Christophe F, Shimada Hiroyuki, Jodele Sonata, Groshen Susan, Ye Wei, Shalinsky David R, Werb Zena, Coussens Lisa M, DeClerck Yves A
Department of Pediatrics and Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Cancer Res. 2004 Mar 1;64(5):1675-86. doi: 10.1158/0008-5472.can-03-0160.
Advanced stages of neuroblastoma show increased expression of matrix metalloproteinases MMP-2 and MMP-9, that have been implicated in many steps of tumor progression, suggesting that they play a contributory role. Using pharmacological and genetic approaches, we have examined the role of these MMPs in progression of SK-N-BE (2).10 human neuroblastoma tumors orthotopically xenotransplanted into immunodeficient mice. Mice treated with Prinomastat, a synthetic inhibitor of MMPs, showed an inhibition of tumor cell proliferation in implanted tumors and a prolonged survival (50 versus 39 days in control group, P < 0.035). Treatment with Prinomastat did not affect formation of liver metastases (P = 0.52) but inhibited intravascular colonization by the tumor cells in the lung by 73.8% (P = 0.03) and angiogenesis in both primary tumors and experimental liver metastases. The primary tumors from Prinomastat-treated mice showed a 39.3% reduction in endothelial area detected by PECAM/CD31 staining in tumor sections (P < 0.001), primarily due to the presence of smaller vessels (P = 0.004). MMP-2 is expressed by neuroblastoma tumor cells and stromal cells, whereas MMP-9 is exclusively expressed by stromal cells, particularly vascular cells. To examine the contribution of MMP-9 to tumor angiogenesis, we generated RAG1/MMP-9 double-deficient mice. We observed a significant inhibition of angiogenesis in the immunodeficient RAG1/MMP-9 double-deficient mice orthotopically implanted with tumor cells (P = 0.043) or implanted s.c. with a mixture of tumor cells and Matrigel (P < 0.001). Using an FITC-labeled lectin, we demonstrated an inhibition in the architecture of the tumor vasculature in MMP-9-deficient mice, resulting in fewer and smaller blood vessels. These changes were associated with a 48% decrease in pericytes present along microvessels. Taken together, the data demonstrate that in neuroblastoma, stromally derived MMP-9 contributes to angiogenesis by promoting blood vessel morphogenesis and pericyte recruitment.
神经母细胞瘤晚期显示基质金属蛋白酶MMP - 2和MMP - 9的表达增加,它们与肿瘤进展的许多步骤有关,表明它们起到了促进作用。我们使用药理学和遗传学方法,研究了这些基质金属蛋白酶在原位异种移植到免疫缺陷小鼠体内的SK - N - BE(2).10人神经母细胞瘤肿瘤进展中的作用。用MMPs的合成抑制剂普林司他治疗的小鼠,其植入肿瘤中的肿瘤细胞增殖受到抑制,生存期延长(对照组为39天,治疗组为50天,P < 0.035)。普林司他治疗不影响肝转移的形成(P = 0.52),但可使肿瘤细胞在肺内的血管内定植减少73.8%(P = 0.03),并抑制原发性肿瘤和实验性肝转移中的血管生成。普林司他治疗小鼠的原发性肿瘤,通过肿瘤切片中PECAM/CD31染色检测到内皮面积减少39.3%(P < 0.001),主要是由于存在较小的血管(P = 0.004)。MMP - 2由神经母细胞瘤肿瘤细胞和基质细胞表达,而MMP - 9仅由基质细胞特别是血管细胞表达。为了研究MMP - 9对肿瘤血管生成的作用,我们构建了RAG1/MMP - 9双缺陷小鼠。我们观察到,原位植入肿瘤细胞的免疫缺陷RAG1/MMP - 9双缺陷小鼠(P = 0.043)或皮下植入肿瘤细胞与基质胶混合物的小鼠(P < 0.001)中,血管生成受到显著抑制。使用异硫氰酸荧光素标记的凝集素,我们证明了MMP - 9缺陷小鼠肿瘤脉管系统结构受到抑制,导致血管数量减少且管径变小。这些变化与沿微血管的周细胞减少48%有关。综上所述,数据表明在神经母细胞瘤中,基质来源的MMP - 9通过促进血管形态发生和周细胞募集,对血管生成起到作用。